Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia.
Cancer J. 2012 Mar-Apr;18(2):208-12. doi: 10.1097/PPO.0b013e31824b2890.
Brain metastases occur commonly in patients with metastatic melanoma, are associated with a poor prognosis, and cause significant morbidity. Both surgery and stereotactic radiosurgery are used to control brain metastases and, in selected patients, improve survival. In those with extensive brain involvement, whole-brain radiotherapy can alleviate symptoms. Historically, systemic therapy has had little role to play in the management of melanoma brain metastases; however, early clinical trials of BRAF inhibitors have shown promising activity. This review examines the evidence for local and systemic treatments in the management of patients with melanoma brain metastases. We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors.
脑转移瘤在转移性黑色素瘤患者中很常见,与预后不良有关,并导致严重的发病率。手术和立体定向放射外科都被用于控制脑转移瘤,并在选择的患者中提高生存率。在广泛脑转移的患者中,全脑放疗可以缓解症状。历史上,系统治疗在黑色素瘤脑转移的治疗中作用不大;然而,BRAF 抑制剂的早期临床试验显示出了有希望的活性。这篇综述检查了局部和全身治疗在管理黑色素瘤脑转移患者中的证据。我们为有脑转移的黑色素瘤患者提出了一种新的治疗方案,该方案整合了 BRAF 抑制剂使用的不断发展的证据。